Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02454959 · ClinicalTrials.gov registry record · Phase 3
Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD
A Phase 3 study, sponsored by Pearl Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 80
- Enrollment target
NCT02454959 is a Phase 3 study that has completed, run by Pearl Therapeutics. The registered enrollment target is 80 participants.
The verdict
NCT02454959, a Phase 3 study, has completed, sponsored by Pearl Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 80 participants
- Enrollment target
Study Summary
This is a Randomized, Phase III, Two-period, Open-label, Chronic-dosing (7 Days), Multi-center, Crossover Study to Assess the Efficacy of PT003 in Subjects with Moderate to Severe COPD with and without a Valved Holding Chamber.
Interventions
- DEVICE GFF MDI (PT003) with Aerochamber
- DEVICE GFF MDI (PT003) without Aerochamber
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2015-05-01 |
| Est. Completion | 2016-03-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02454959
The ClinicalTrials.gov registry entry for NCT02454959 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pearl Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GFF MDI (PT003) with Aerochamber is the first listed.
NCT02454959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02454959 about?
NCT02454959 is a clinical study titled "Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD". This is a Randomized, Phase III, Two-period, Open-label, Chronic-dosing (7 Days), Multi-center, Crossover Study to Assess the Efficacy of PT003 in Subjects with Moderate to Severe COPD with and without a Valved Holding Chamber.
What is the current status of trial NCT02454959?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2015-05-01. Estimated completion is 2016-03-25.
What interventions are being tested in trial NCT02454959?
The interventions under investigation include: GFF MDI (PT003) with Aerochamber (DEVICE), GFF MDI (PT003) without Aerochamber (DEVICE).
Who is sponsoring clinical trial NCT02454959?
This trial is sponsored by Pearl Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.